nach oben

BioDrugs

Erschienen in:

01.04.2009 | Drug Development

Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

verfasst von: Ryan J.O. Dowling, Michael Pollak, Dr Nahum Sonenberg

Erschienen in: BioDrugs | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in the regulation of cellular growth, survival, and proliferation. Inappropriate activation of PI3K/Akt/mTOR signaling can promote a cellular environment that is favorable for transformation. In fact, dysregulation of this pathway, as a result of genetic mutations and amplifications, is implicated in a variety of human cancers. Therefore, mTOR has emerged as a key target for the treatment of cancer, particularly in the treatment of tumors that exhibit increased mTOR signaling as a result of genetic lesions. The immunosuppressant sirolimus (rapamycin) directly inhibits mTOR activity and suppresses the growth of cancer cells in vitro and in vivo. As a result, a number of sirolimus derivatives have been developed as anti-cancer therapies, and these compounds are currently under investigation in phase I–III clinical trials. In this review, we summarize the use of sirolimus derivatives in clinical trials and address some of the challenges associated with targeting mTOR for the treatment of human cancer.

Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004 May; 4(5): 335–48PubMedCrossRef

Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004 Aug 15; 18(16): 1926–45PubMedCrossRef

Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005 Aug; 11(8): 353–61PubMedCrossRef

Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer [abstract no. 3003]. Annual Meeting, American Society of Clinical Oncology; 2006 Jun 2–6; Atlanta (GA)

Le Tourneau C, Faivre S, Serova M, et al. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008 Oct 21;99(8): 1197–203PubMedCrossRef

Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 May 31; 356(22): 2271–81PubMedCrossRef

Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991 Aug 23; 253(5022): 905–9PubMedCrossRef

Kunz J, Henriquez R, Schneider U, et al. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 1993 May 7; 73(3): 585–96PubMedCrossRef

Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994 Jul 15; 78(1): 35–43PubMedCrossRef

10.

Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756–8PubMedCrossRef

11.

Petroulakis E, Mamane Y, Le Bacquer O, et al. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006 Jan 30; 94(2): 195–9PubMedCrossRef

12.

Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007 Aug; 17(8): 666–81PubMedCrossRef

13.

Schalm SS, Fingar DC, Sabatini DM, et al. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 2003 May 13; 13(10): 797–806PubMedCrossRef

14.

Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002 Jul 26; 110(2): 177–89PubMedCrossRef

15.

Schalm SS, Blenis J. Identification of a conserved motif required for mTOR signaling. Curr Biol 2002 Apr 16; 12(8): 632–9PubMedCrossRef

16.

Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003 May 2; 278(18): 15461–4PubMedCrossRef

17.

Vander Haar E, Lee SI, Bandhakavi S, et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007 Mar; 9(3): 316–23PubMedCrossRef

18.

Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007 Mar 23; 25(6): 903–15PubMedCrossRef

19.

Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006 Sep; 6(9): 729–34PubMedCrossRef

20.

Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006 Oct 6; 127(1): 125–37PubMedCrossRef

21.

Pestova TV, Lorsch JR, Hellen CUT. The mechanism of translation initiation in eukaryotes. In: Mathews MB, Sonenberg N, Hershey JWB, editors. Translational control in biology and medicine. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2007: 87–128

22.

Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68: 913–63PubMedCrossRef

23.

Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 2005 Apr; 6(4): 318–27PubMedCrossRef

24.

Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001 Apr 1; 15(7): 807–26PubMedCrossRef

25.

Pause A, Belsham GJ, Gingras AC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 1994 Oct 27; 371(6500): 762–7PubMedCrossRef

26.

Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999 Jun 1; 13(11): 1422–37PubMedCrossRef

27.

Shahbazian D, Roux PP, Mieulet V, et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 2006 Jun 21; 25(12): 2781–91PubMedCrossRef

28.

Richardson CJ, Broenstrup M, Fingar DC, et al. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr Biol 2004 Sep 7; 14(17): 1540–9PubMedCrossRef

29.

Raught B, Gingras AC, Gygi SP, et al. Serum-stimulated, rapamycinsensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 2000 Feb 1; 19(3): 434–44PubMedCrossRef

30.

Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A 2001 Jun 19; 98(13): 7037–44PubMedCrossRef

31.

Barnhart BC, Simon MC. Taking aim at translation for tumor therapy. J Clin Invest 2007 Sep; 117(9): 2385–8PubMedCrossRef

32.

Mamane Y, Petroulakis E, Rong L, et al. eIF4E: from translation to transformation. Oncogene 2004 Apr 19; 23(18): 3172–9PubMedCrossRef

33.

De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004 Apr 19; 23(18): 3189–99PubMedCrossRef

34.

Mamane Y, Petroulakis E, Martineau Y, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2007; 2: e242PubMedCrossRef

35.

Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990 Jun 7; 345(6275): 544–7PubMedCrossRef

36.

Lazaris-Karatzas A, Sonenberg N. The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol Cell Biol 1992 Mar; 12(3): 1234–8PubMed

37.

Avdulov S, Li S, Michalek V, et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004 Jun; 5(6): 553–63PubMedCrossRef

38.

Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004 May; 10(5): 484–6PubMedCrossRef

39.

Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004 Mar 18; 428(6980): 332–7PubMedCrossRef

40.

De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999 Jan; 31(1): 59–72PubMedCrossRef

41.

Clemens MJ, Bommer UA. Translational control: the cancer connection. Int J Biochem Cell Biol 1999 Jan; 31(1): 1–23PubMedCrossRef

42.

Bauer C, Brass N, Diesinger I, et al. Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma. Int J Cancer 2002 Mar 10; 98(2): 181–5PubMedCrossRef

43.

Bauer C, Diesinger I, Brass N, et al. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 2001 Aug 15; 92(4): 822–9PubMedCrossRef

44.

Eberle J, Krasagakis K, Orfanos CE. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer 1997 May 2; 71(3): 396–401PubMedCrossRef

45.

Rousseau D, Gingras AC, Pause A, et al. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996 Dec 5; 13(11): 2415–20PubMed

46.

Polunovsky VA, Gingras AC, Sonenberg N, et al. Translational control of the antiapoptotic function of Ras. J Biol Chem 2000 Aug 11; 275(32): 24776–80PubMedCrossRef

47.

Armengol G, Rojo F, Castellvi J, et al. 4E-Binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res 2007 Aug 15; 67(16): 7551–5PubMedCrossRef

48.

Castellvi J, Garcia A, Rojo F, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006 Oct 15; 107(8): 1801–11PubMedCrossRef

49.

Fumagalli S, Thomas G. S6 Phosphorylation and signal transduction. In: Sonenberg N, Hershey JWB, Mathews MB, editors. Translational control of gene expression. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2000: 695–717

50.

Shima H, Pende M, Chen Y, et al. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 1998 Nov 16; 17(22): 6649–59PubMedCrossRef

51.

Dowling RJ, Zakikhani M, Fantus IG, et al. metformin inhibits mammalian target of rapamycin dependent translation initiation in breast cancer cells. Cancer Res 2007 Nov 15; 67(22): 10804–12PubMedCrossRef

52.

Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003 Aug 1; 17(15): 1829–34PubMedCrossRef

53.

Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002 Sep; 4(9): 648–57PubMedCrossRef

54.

Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006 Aug; 5(8): 671–88PubMedCrossRef

55.

Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 2001; 3(5): 304–12PubMedCrossRef

56.

Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001 Oct 15; 61(20): 7426–9PubMed

57.

Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003 Oct; 4(4): 257–62PubMedCrossRef

58.

Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005 Jun 1; 65(11): 4562–7PubMedCrossRef

59.

Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999 Feb 16; 96(4): 1563–8PubMedCrossRef

60.

Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001 Aug 28; 98(18): 10314–9PubMedCrossRef

61.

Koksal IT, Dirice E, Yasar D, et al. The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004 Jul–Aug; 22(4): 307–12PubMedCrossRef

62.

Kanamori Y, Kigawa J, Itamochi H, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001 Apr; 7(4): 892–5PubMed

63.

Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000 Feb 18; 100(4): 387–90PubMedCrossRef

64.

Stambolic V, Tsao MS, Macpherson D, et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/−mice. Cancer Res 2000 Jul 1; 60(13): 3605–11PubMed

65.

Di Cristofano A, Pesce B, Cordon-Cardo C, et al. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998 Aug; 19(4): 348–55PubMedCrossRef

66.

Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003 Sep; 4(3): 209–21PubMedCrossRef

67.

Jaeschke A, Hartkamp J, Saitoh M, et al. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 2002 Oct 28; 159(2): 217–24PubMedCrossRef

68.

Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003 Nov 26; 115(5): 577–90PubMedCrossRef

69.

Onda H, Lueck A, Marks PW, et al. Tsc2(+/−) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999 Sep; 104(6): 687–95PubMedCrossRef

70.

Kobayashi T, Minowa O, Kuno J, et al. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999 Mar 15; 59(6): 1206–11PubMed

71.

Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003 Nov 11; 13(22): 2004–8PubMedCrossRef

72.

Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2(4): 28PubMedCrossRef

73.

Kahn BB, Alquier T, Carling D, et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005 Jan; 1(1): 15–25PubMedCrossRef

74.

Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004 Jul; 6(1): 91–9PubMedCrossRef

75.

Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998 Jan 8; 391(6663): 184–7PubMedCrossRef

76.

Bardeesy N, Sinha M, Hezel AF, et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002 Sep 12; 419(6903): 162–7PubMedCrossRef

77.

Weinstein IB. Cancer: addiction to oncogenes —the Achilles heal of cancer. Science 2002 Jul 5; 297(5578): 63–4PubMedCrossRef

78.

Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006 Oct 16; 25(48): 6436–46PubMedCrossRef

79.

Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic: I, taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975 Oct; 28(10): 721–6CrossRef

80.

Choi J, Chen J, Schreiber SL, et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996 Jul 12; 273(5272): 239–42PubMedCrossRef

81.

Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007 Oct; 13(10): 433–42PubMedCrossRef

82.

Oshiro N, Yoshino K, Hidayat S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004 Apr; 9(4): 359–66PubMedCrossRef

83.

Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004 Nov; 6(11): 1122–8PubMedCrossRef

84.

Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005 Apr 1; 65(7): 2825–31PubMedCrossRef

85.

Mosley JD, Poirier JT, Seachrist DD, et al. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 2007 Aug; 6(8): 2188–97PubMedCrossRef

86.

Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001 Sep; 8(3): 249–58PubMedCrossRef

87.

Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004 Feb 1; 10(3): 1013–23PubMedCrossRef

88.

Beretta L, Gingras AC, Svitkin YV, et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996 Feb 1; 15(3): 658–64PubMed

89.

Grolleau A, Bowman J, Pradet-Balade B, et al. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem 2002 Jun 21; 277(25): 22175–84PubMedCrossRef

90.

Huang S, Liu LN, Hosoi H, et al. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001 Apr 15; 61(8): 3373–81PubMed

91.

Abraham RT, Eng CH. Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 2008 Feb; 12(2): 209–22PubMedCrossRef

92.

Tsang CK, Qi H, Liu LF, et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007 Feb; 12(3-4): 112–24PubMedCrossRef

93.

Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006 Oct 1; 12(19): 5755–63PubMedCrossRef

94.

Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004 Jun 15; 22(12): 2336–47PubMedCrossRef

95.

Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005 Aug 10; 23(23): 5314–22PubMedCrossRef

96.

Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 Mar 1; 22(5): 909–18PubMedCrossRef

97.

Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005 Aug 10; 23(23): 5347–56PubMedCrossRef

98.

O’Donnell A, Faivre S, Judson I, et al. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmaco-dynamic (PD) endpoints in patients with solid tumours [abstract no. A803]. Annual Meeting, American Society of Clinical Oncology; 2003 May 31–Jun 3; Chicago (IL)

99.

Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004 Jan 1; 64(1): 252–61PubMedCrossRef

100.

Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006 Jun; 17(5): 487–94PubMedCrossRef

101.

Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006 Sep 1; 12(17): 5165–73PubMedCrossRef

102.

Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 Aug 9; 372(9637): 449–56PubMedCrossRef

103.

Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008 Jan 20; 26(3): 361–7PubMedCrossRef

104.

Iwenofu OH, Lackman RD, Staddon AP, et al. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008 Mar; 21(3): 231–7PubMedCrossRef

105.

Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005 Feb 18; 307(5712): 1098–101PubMedCrossRef

106.

Bayascas JR, Alessi DR. Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell 2005 Apr 15; 18(2): 143–5PubMedCrossRef

107.

Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006 Apr 21; 22(2): 159–68PubMedCrossRef

108.

Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004 Nov 8; 167(3)

109.

Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/ Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004 Sep 21; 14(18): 1650–6PubMedCrossRef

110.

Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004 Jul 19;166(2): 213-23

111.

Greene MW, Sakaue H, Wang L, et al. Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation. J Biol Chem 2003 Mar 7; 278(10): 8199–211PubMedCrossRef

112.

O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006 Feb 1;66(3): 1500–8PubMedCrossRef

113.

Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007 Mar; 117(3): 730–8PubMedCrossRef

114.

Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006 Nov; 5(11): 2676–84PubMedCrossRef

115.

Skeen JE, Bhaskar PT, Chen CC, et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 2006 Oct; 10(4): 269–80PubMedCrossRef

116.

Wang MY, Lu KV, Zhu S, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006 Aug 15; 66(16): 7864–9PubMedCrossRef

117.

Birle DC, Hedley DW. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts. Mol Cancer Ther 2006 Oct; 5(10): 2494–502PubMedCrossRef

118.

Azzariti A, Porcelli L, Gatti G, et al. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 2008 Mar 1; 75(5): 1035–44PubMedCrossRef

119.

Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006 Jul 11; 67(1): 156–8PubMedCrossRef

120.

Milton DT, Riely GJ, Azzoli CG, et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007 Aug 1; 110(3): 599–605PubMedCrossRef

121.

Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005 Mar 25; 120(6): 747–59PubMedCrossRef

122.

Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004 Oct 15; 10(20): 7031–42PubMedCrossRef

123.

Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004 Dec 15; 104(13): 4188–93PubMedCrossRef

124.

Mohi MG, Boulton C, Gu TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 2004 Mar 2; 101(9): 3130–5PubMedCrossRef

125.

de Graffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004 Dec 1; 10(23): 8059–67CrossRef

126.

Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008 Jan; 44(1): 84–91PubMedCrossRef

127.

Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006; 13(2): 137–44PubMedCrossRef

128.

Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005 Aug 18; 24(35): 5414–22PubMedCrossRef

129.

Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice. Proc Natl Acad Sci U S A 2001 Aug 28; 98(18): 10320–5PubMedCrossRef

130.

Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002 Sep 1; 62(17): 5027–34PubMed

131.

Uegaki K, Kanamori Y, Kigawa J, et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 2005 Aug; 14(2): 389–92PubMed

132.

Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997 Sep 15; 57(18): 3935–40PubMed

133.

Wendel HG, Malina A, Zhao Z, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006 Aug 1; 66(15): 7639–46PubMedCrossRef

134.

Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005 Aug 10; 23(23): 5294–304PubMedCrossRef

135.

Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005 Sep 1; 104(5): 1045–8PubMedCrossRef

136.

Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005 Aug; 23(4): 357–61PubMedCrossRef

137.

Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007 Jan 15; 13 (2 Pt 2): 758s–63sPubMedCrossRef

138.

Dilling MB, Germain GS, Dudkin L, et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002 Apr 19; 277(16): 13907–17PubMedCrossRef

139.

Aguirre D, Boya P, Bellet D, et al. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004 Nov; 9(6): 797–805PubMedCrossRef

140.

Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009 Feb 10; 7(2): e38PubMedCrossRef

141.

Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009 Mar 20; 284(12): 8023–32PubMedCrossRef

142.

Howes AL, Chiang GG, Lang ES, et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007 Sep; 6(9): 2505–14PubMedCrossRef

143.

Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP 16. Oncogene 2006 Oct 26; 25(50): 6648–59PubMedCrossRef

144.

Schultz RM, Merriman RL, Andis SL, et al. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995 Jul–Aug; 15(4): 1135–9PubMed

145.

Ward S, Sotsios Y, Dowden J, et al. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003 Mar; 10(3): 207–13PubMedCrossRef

146.

Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006 May; 9(5): 341–9PubMedCrossRef

147.

DeFeo-Jones D, Barnett SF, Fu S, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005 Feb; 4(2): 271–9PubMed

148.

Rattan R, Giri S, Singh AK, et al. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005 Nov 25; 280(47): 39582–93PubMedCrossRef

149.

Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006 Nov 1; 66(21): 10269–73PubMedCrossRef

150.

Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007 Jul 15; 67(14): 6745–52PubMedCrossRef

151.

Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 Jun 4; 330(7503): 1304–5PubMedCrossRef

152.

Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008 Dec; 8: 915–28PubMedCrossRef

153.

Ballou LM, Selinger ES, Choi JY, et al. Inhibition ofmammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem 2007 Aug 17; 282(33): 24463–70PubMedCrossRef

Titel: Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy
verfasst von: Ryan J.O. Dowling
Michael Pollak
Dr Nahum Sonenberg
Publikationsdatum: 01.04.2009
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 2/2009
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/00063030-200923020-00002

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

Targeted Therapy for Kaposi Sarcoma

Golimumab

Biologic Therapy for Rheumatoid Arthritis